News in other languages: HANDOK Inc.

27/07/23

Hogere omzet en kleiner verlies voor Argenx

Managers and Directors: HANDOK Inc.

Manager	Title	Age	Since
Jin-Ki Baik CEO	Chief Executive Officer	69	-
Young-Jin Kim CEO	Chief Executive Officer	68	01/01/1996
Hyeon-Cheol Lee DFI	Director of Finance/CFO	58	-

Director	Title	Age	Since
Young-Jin Kim CHM	Chairman	68	01/01/1996
Jin-Ki Baik BRD	Director/Board Member	69	-
Young Kim BRD	Director/Board Member	58	-

More insiders

Handok Inc is a Korea-based company primarily engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through four segments. The Pharmaceutical segment mainly manufactures and sells prescription and over-the-counter drugs, including treatments for diabetes, hypertension, kidney diseases, respiratory diseases, central nervous system disorders, rare diseases, as well as anticancer drugs. The Medical Device segment mainly sells medical devices and diagnostic reagents. The Contract Manufacturing segment mainly provides contract manufacturing and quality control services for pharmaceuticals. The Real Estate Leasing segment mainly engages in the real estate leasing business.

Employees

940

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
23/07/26	₩8,580.00	+2.51%	9,396
22/07/26	₩8,370.00	+1.70%	9,917
21/07/26	₩8,230.00	-0.96%	32,202
20/07/26	₩8,310.00	-1.07%	20,461
16/07/26	₩8,400.00	+3.45%	26,418

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Korea S.E. Other stock markets 23/07/2026			5-day change	1st Jan Change
8,580.00 ^KRW	+2.51%		+5.67%	-23.39%

04-30	Handok Q1 operating profit 207 million won, swings to profit from year earlier	RE
02-11	HANDOK Inc. announces Annual dividend, payable on April 24, 2026	CI

Market Cap	111B 75.56M 66.45M 61.73M 56.78M 106M 7.32B 108M 738M 288M 3.57B 284M 278M 12.38B	P/E 2024	-3.16x	P/E 2025	-69x
Enterprise Value	462B 313M 275M 256M 235M 441M 30.33B 449M 3.06B 1.19B 14.79B 1.18B 1.15B 51.32B	EV / Sales 2024	0.95x	EV / Sales 2025	0.93x
Free-Float	52.22%	Yield 2024	1.66%	Yield 2025	-

04-30	Handok Q1 operating profit 207 million won, swings to profit from year earlier	RE
02-11	HANDOK Inc. announces Annual dividend, payable on April 24, 2026	CI
02-10	Handok Q4 operating profit 4.2 billion won, swings to profit from year earlier	RE
30/10/25	Handok Q3 operating profit 287 million won, swings to profit from year earlier	RE
10/09/25	Teva Handok Announces UZEDY Receives Regulatory Approval from the South Korean Ministry of Food and Drug Safety	CI
12/05/25	Handok To Divest 9 Billion Won Worth Of Own Shares	RE
30/04/25	Handok Q1 Operating Loss 1.6 Billion Won	RE
05/02/25	Handok Q4 Operating Loss 2.7 Billion Won	RE
09/12/24	HANDOK Inc. announced that it expects to receive KRW 30 billion in funding	CI
26/06/24	WELT Corp., Ltd announced that it has received KRW 14 billion in funding from Envisioning Partners, Korea Development Bank, Investment Arm, Shinhan Venture Investment Co, Ltd., IMM Investment, Corp., HANDOK Inc.	CI
24/05/24	Biocon Ties Up with Handok to Market Anti-Diabetic Drug Liraglutide in South Korea	MT
24/05/24	Biocon Limited Signs Exclusive Licensing and Supply Deal for the Commercialization of Liraglutide in South Korea with Handok Inc	CI
16/04/24	Nxera Pharma Partners with Handok c. to Distribute PIVLAZ in South Korea,	MT

14/02/24	Sobi and Handok establish joint venture for rare disease business in South Korea	AQ
03/04/17	Handok : Genexine Releases Positive Interim Phase 2 Clinical Data from PGHD Trial with long-acting growth hormone, GX-H9 at ENDO 2017	BU

HANDOK Inc. Stock

Stocks

A002390

KR7002390003

Pharmaceuticals

Valuation: HANDOK Inc.

Chart: HANDOK Inc.

Latest news : HANDOK Inc.

Press Releases: HANDOK Inc.

News in other languages: HANDOK Inc.

Quotes and Performance

Course Extremes

Managers and Directors: HANDOK Inc.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	+2.51%
1 week	+5.67%
Current month	+21.36%
1 month	+15.48%
3 months	-17.02%
6 months	-19.89%
Current year	-23.39%

1 week	7,920	8,650
1 month	6,460	8,650
Current year	6,460	11,820
1 year	6,460	13,460
3 years	6,460	20,300
5 years	6,460	28,150
10 years	6,460	44,750

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
HANDOK INC.	+2.51%	+5.67%	-28.74%	-37.46%	73.63M
ELI LILLY AND COMPANY	+1.57%	+1.16%	+48.05%	+157.51%	1,037B
JOHNSON & JOHNSON	+1.17%	+3.35%	+52.77%	+51.00%	615B
ABBVIE INC.	+1.09%	+0.57%	+34.27%	+78.69%	448B
ROCHE HOLDING AG	+5.14%	+5.40%	+33.75%	+27.79%	326B
NOVARTIS AG	+1.85%	+3.57%	+37.09%	+40.59%	293B
ASTRAZENECA PLC	-0.11%	+0.48%	+18.87%	+17.70%	264B
NOVO NORDISK A/S	+0.25%	-4.62%	-27.66%	-41.76%	216B
AMGEN INC.	+0.75%	-0.87%	+19.12%	+56.47%	198B
GILEAD SCIENCES, INC.	-0.10%	-4.55%	+14.56%	+67.52%	162B
Average	+1.37%	+1.22%	+20.21%	+41.80%	355.75B
Weighted average by Cap.	+1.41%	+1.47%	+35.04%	+75.51%

	2024	2025
Net sales	507B 344M 302M 281M 258M 485M 33.31B 493M 3.36B 1.31B 16.25B 1.29B 1.26B 56.36B	535B 363M 319M 296M 273M 511M 35.13B 520M 3.54B 1.38B 17.13B 1.36B 1.33B 59.44B
Net income	-52.56B -35.63M -31.34M -29.11M -26.77M -50.21M -3.45B -51.11M -348M -136M -1.68B -134M -131M -5.84B	-2.15B -1.46M -1.28M -1.19M -1.1M -2.06M -141M -2.09M -14.26M -5.56M -68.94M -5.48M -5.36M -239M
Net Debt	317B 215M 189M 176M 162M 303M 20.83B 309M 2.1B 820M 10.16B 808M 790M 35.25B	351B 238M 209M 194M 179M 335M 23.01B 341M 2.32B 905M 11.22B 892M 873M 38.94B